Population pharmacokinetics of the novel anticancer agent KRN7000

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2002-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-001-0413-3PMID 11914907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro.

  2000cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000.

  1998cited by this paper
• CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

  1997cited by this paper
• Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors.

  1997cited by this paper
• Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice.

  1996cited by this paper
• Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.

  1996cited by this paper
• Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.

  1995cited by this paper
• An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells

  1994cited by this paper
• An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans

  1994cited by this paper
• Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

  1992cited by this paper
• The synergistic effect

  1965cited by this paper

• Potential of Polar Lipids Isolated from the Marine Sponge Haliclona (Halichoclona) vansoesti against Melanoma

  2024cites this paper
• Polar functional group-containing glycolipid CD1d ligands modulate cytokine-biasing responses and prevent experimental colitis

  2020cites this paper
• Cytotoxic and Antitumor Compounds from Marine Invertebrates

  2020cites this paper
• Function of ex vivo stimulated Natural killer T cells from patients with chronic HIV-1 infection

  2019cites this paper
• Total Synthesis of Marine Glycosphingolipid Vesparioside B.

  2016cites this paper
• Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.

  2014cites this paper
• Cerebrosides from Marine Organisms

  2014cites this paper
• The Influence of Immunization Route on the Adjuvant Effect of alpha-Galactosylceramide

  2013cites this paper
• Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients: Evidence and Therapeutic Opportunities

  2012cites this paper
• The stimulating adventure of KRN 7000.

  2011cites this paper
• Immunologic mapping of glycomes: implications for cancer diagnosis and therapy.

  2011cites this paper
• Introduction of aromatic group on 4'-OH of α-GalCer manipulated NKT cell cytokine production.

  2011cites this paper
• Marine Natural Products and their Synthetic Derivatives for Cancer Therapy

  2010cites this paper
• Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

  2009cites this paper
• Triflic Acid‐Promoted Formylation of Ceramide in Dimethylformamide

  2009cites this paper
• Cross‐regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens

  2009cites this paper
• The contrasting roles of NKT cells in tumor immunity.

  2009cites this paper
• Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

  2008cites this paper
• Clinical status of anti-cancer agents derived from marine sources.

  2008cites this paper
• The role of NKT cells in tumor immunity.

  2008cites this paper
• Synthetic analogs of natural glycosides in drug discovery and development.

  2008cites this paper
• NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis1

  2008cites this paper
• AxisSubsets Define a New Immunoregulatory NKT Cells in Tumor Immunity: Opposing

  2008cites this paper
• Recent advances in the glycosylation of sphingosines and ceramides.

  2007cites this paper
• Total synthesis of agelagalastatin.

  2006cites this paper
• The immunological function of iGb3.

  2006cites this paper
• Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors.

  2005cites this paper
• Efficient Synthesis of α-Galactosyl Ceramide Analogues Using Glycosyl Iodide Donors

  2005cites this paper
• Vesparioside from the Marine Sponge Spheciospongia vesparia, the First Diglycosylceramide with a Pentose Sugar Residue

  2005cites this paper
• Fatty acids from lipids of marine organisms: molecular biodiversity, roles as biomarkers, biologically active compounds, and economical aspects.

  2005cites this paper
• Chemical diversity of bioactive marine natural products: an illustrative case study.

  2004cites this paper
• Glycolipids from sponges. 13. Clarhamnoside, the first rhamnosylated alpha-galactosylceramide from Agelas clathrodes. Improving spectral strategies for glycoconjugate structure determination.

  2004cites this paper
• Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption.

  2004cites this paper
• The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity.

  2004cites this paper
• Marine natural products and related compounds in clinical and advanced preclinical trials.

  2004cites this paper
• Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells

  2003cites this paper
• MOLECULAR TARGETS FOR THERAPY (MTT)

  2003cites this paper
• Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmacokinetics and Drug Therapy presented at Uppsala University in 2002

  2002cites this paper
• ! " ! # Blockin Blockin Blockin$ % Evaluation of Type I Error Rates When Modeling Ordered Categorical Data in Nonmem, in Manuscript Models Specific to Time-varying Covariates; Application in Population Pharmacokinetic-pharmacodynamic Model Building, in Manuscript Pharmacokinetic Modeling of Saturabl

  year unknowncites this paper